Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma
Datta, M.; Chatterjee, S.; Perez, E. M.; Gritsch, S.; Roberge, S.; Duquette, M.; Chen, I. X.; Naxerova, K.; Kumar, A. S.; Ghosh, M.; Emblem, K. E.; Ng, M. R.; Ho, W. W.; Kumar, P.; Krishnan, S.; Dong, X.; Speranza, M. C.; Neagu, M. R.; Reardon, D. A.; Sharpe, A. H.; Freeman, G. J.; Suva, M. L.; Xu, L.; Jain, R. K.
Show abstract
Immune checkpoint blockers (ICBs) have failed in all Phase III glioblastoma trials. Here, we found that ICBs induce cerebral edema in some patients and mice with glioblastoma. Through single-cell RNA sequencing, intravital imaging, and T cell blocking studies in mice, we demonstrated that this edema results from an inflammatory response following anti-PD1 antibody treatment that disrupts the blood-tumor-barrier. Used in lieu of immunosuppressive corticosteroids, the angiotensin receptor blocker losartan prevented this ICB-induced edema and reprogrammed the tumor microenvironment, curing 20% of mice which increased to 40% in combination with standard of care treatment. Using a bihemispheric tumor model, we identified a "hot" tumor immune signature prior to losartan+anti-PD1 therapy that predicted long-term survival. Our findings provide the rationale and associated biomarkers to test losartan with ICBs in glioblastoma patients. One-Sentence SummaryLosartan prevents immunotherapy-associated edema and enhances the outcome of immunotherapy in glioblastoma.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SLIT2-ROBO signaling in tumor-associated microglia/macrophages drives glioblastoma immunosuppression and vascular dysmorphia 97%
- Tumor cell-derived spermidine promotes a pro-tumorigenic immune microenvironment in glioblastoma via CD8+ T cell inhibition 95%
- Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer 95%
Similar papers in this journal
Similar papers in this journal
- An mRNA-encoded, long-lasting Interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers 94%
- Single-cell landscapes of primary glioblastomas and matched organoids and cell lines reveal variable retention of inter- and intra-tumor heterogeneity 94%
- De Novo Pyrimidine Synthesis is a Targetable Vulnerability in IDH Mutant Glioma 94%
Similar papers in this journal
- IDH-Tau-EGFR triad defines the neovascular landscape of diffuse gliomas by controlling mesenchymal differentiation 93%
- Augmentation of DNA exonuclease TREX1 in macrophages as a therapy for cardiac ischemic injury 92%
- Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.